MedTrace Logo

Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants

NCT03325075 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-06-10

Study results available
· View outcomes & findings →

Summary

This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.

Conditions

  • Chikungunya Virus

Interventions

BIOLOGICAL

VAL-181388

Escalating dose levels

OTHER

Placebo

Saline

Sponsors & Collaborators

  • Defense Advanced Research Projects Agency

    collaborator FED

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-19
Primary Completion
2019-03-19
Completion
2019-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03325075 on ClinicalTrials.gov